Lynn Kirkpatrick News Today

SAN DIEGO, CA / ACCESSWIRE / May 28, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical stage pharmaceutical company developing innovative solutions for severe pain

Ensysce Biosciences’ CEO Dr. Lynn Kirkpatrick Featured in Xtalks Clinical ...

25.04.2024 - ~ Dr. Kirkpatrick Leads the Companys Unique Response to Effectively Reduce Prescription Drug Overdose and Abuse ~SAN DIEGO, CA / ACCESSWIRE / April 25, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) (Ensysce or the Company), a clinical stage ... Seite 1

Ensysce Biosciences Presentation from the Noble Capital Markets Emerging ...

Ensysce Biosciences Selected to Present at American Association of ...

By Rob Curran Shares of Ensysce Biosciences rallied after the developer of pain medication intended to be less prone to abuse received feedback from the Food...

Ensysce Biosciences to Present Groundbreaking Oral Overdose Protection ...

Ensysce Biosciences Announces FDA Breakthrough Therapy Designation ...

Ensysce Biosciences Inc (NASDAQ:ENSC) received an FDA Breakthrough Therapy Designation (BTD) for PF614-MPAR, a next-generation opioid. BTD has been granted to fewer than 300 drugs. It is designed to expedite the development and reviewing of drugs intended to treat a serious condition where preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over available therapies. PF614-MPAR is designed to provide optimal pain relief at prescribed doses yet limit accid

The FDA has granted Breakthrough Therapy designation to PF614-MPAR, an oral opioid analgesic designed with overdose protection.